These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 25376287

  • 1. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [Abstract] [Full Text] [Related]

  • 2. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B, Byrne M, Kim R.
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [Abstract] [Full Text] [Related]

  • 6. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA, Zee BC, Cheung FY, Kwong P, Chiang CL, Leung KC, Siu SW, Lee C, Lai M, Kwok C, Chong M, Jolivet J, Tung S.
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [Abstract] [Full Text] [Related]

  • 7. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 8. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C, Poggi G, Missale G, Fanello S, Salvagni S, Ardizzoni A, Maria SE.
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O.
    Oncology; 2014 Aug; 87(6):330-41. PubMed ID: 25227534
    [Abstract] [Full Text] [Related]

  • 10. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 11. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.
    J Clin Gastroenterol; 2014 Mar 26; 48(3):e22-9. PubMed ID: 24045282
    [Abstract] [Full Text] [Related]

  • 12. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF.
    Radiology; 2015 Nov 26; 277(2):594-603. PubMed ID: 26069923
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.
    J Hepatol; 2012 Oct 26; 57(4):821-9. PubMed ID: 22727733
    [Abstract] [Full Text] [Related]

  • 14. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.
    Dig Liver Dis; 2013 May 26; 45(5):408-13. PubMed ID: 23182599
    [Abstract] [Full Text] [Related]

  • 15. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
    Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O.
    PLoS One; 2016 May 26; 11(8):e0161303. PubMed ID: 27537374
    [Abstract] [Full Text] [Related]

  • 16. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM.
    J Gastroenterol Hepatol; 2013 Nov 26; 28(11):1756-61. PubMed ID: 23800278
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG.
    Clin Mol Hepatol; 2015 Sep 26; 21(3):287-94. PubMed ID: 26527250
    [Abstract] [Full Text] [Related]

  • 18. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
    Tsukui Y, Mochizuki H, Hoshino Y, Kawakami S, Kuno T, Fukasawa Y, Iwamoto F, Hirose S, Yoshida T, Hosoda K, Suzuki Y, Hosoda K, Kojima Y, Hirose Y, Shindou K, Matsuda M, Yagawa S, Tawara A, Kobayashi M, Konishi T, Yamazaki T, Takahashi S, Fuji H, Enomoto N, Omata M.
    Hepatogastroenterology; 2012 Sep 26; 59(120):2536-9. PubMed ID: 22497953
    [Abstract] [Full Text] [Related]

  • 19. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
    J Clin Oncol; 2013 Oct 01; 31(28):3517-24. PubMed ID: 23980084
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Oct 01; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.